The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Role of FLT3 in leukemia
Abstract
FLT3 is the most frequently mutated gene in cases of acute myelogenous leukemia (AML). About 30 to 35% of patients have either internal tandem duplications (ITDs) in the juxtamembrane domain or mutations in the activating loop of FLT3. FLT3 mutations occur in a broad spectrum of FAB subtypes in adult and pediatric AML and are particularly common in acute promyelocytic leukemia (APL). FLT3 mutations confer a poor prognosis in most retrospective studies. The consequence of either FLT3-ITD or activating loop mutations, which occur predominantly at position D835, is constitutive activation of the tyrosine kinase; FLT3 mutants confer factor-independent growth to Ba/F3 and 32D cells and activate similar transduction pathways as the native receptor in response to ligand, including the STAT, RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3; kinase (PI3K)/AKT pathways. Injection of FLT3-ITD transformed cells, such as Ba/F3 or 32D, into syngeneic recipient mice results in a leukemia-like syndrome, and expression in primary murine bone marrow cells in a retroviral transduction assay results in a myeloproliferative disorder. Mutations that abrogate FLT3 kinase activity result in loss of transforming properties in these assays. Further, FLT3-selective inhibitors impair transformation of primary AML cells that harbor these mutations, and also inhibit FLT3 transformed hematopoietic cell lines, and leukemias induced by activated FLT3 mutants in murine models. Collectively, these data indicate that FLT3 may be a viable therapeutic target for treatment of AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S., Rockwell, P., Witte, L., Burrow, C., Ratajczak, M. Z., & Gewirtz, A. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.459 · Cited by 429
Yergeau, D. A., Hetherington, C. J., Wang, Q., Zhang, P., Sharpe, A. H., Binder, M., Marín-Padilla, M., Tenen, D. G., Speck, N. A., & Zhang, D.-E. (1997) · Nature Genetics · doi:10.1038/ng0397-303 · Cited by 346
Castilla, L. H., Wijmenga, C., Wang, Q., Stacy, T., Speck, N. A., Eckhaus, M., Marín-Padilla, M., Collins, F. S., Wynshaw-Boris, A., & Liu, P. P. (1996) · Cell · doi:10.1016/s0092-8674(00)81388-4 · Cited by 284
Westendorf, J. J., Yamamoto, C. M., Lenny, N., Downing, J. R., Selsted, M. E., & Hiebert, S. W. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.322 · Cited by 270
Cited by
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
van der Velden, V. H. J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., & van Dongen, J. J. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402922 · Cited by 563
Fischer, T., Stone, R. M., DeAngelo, D. J., Galinsky, I., Estey, E., Lanza, C., Fox, E., Ehninger, G., Feldman, E. J., Schiller, G. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9678 · Cited by 504
Self-citationPreferential induction of apoptosis for primary human leukemic stem cells
Guzman, M. L., Swiderski, C. F., Howard, D. S., Grimes, B. A., Rossi, R. M., Szilvassy, S. J., & Jordan, C. T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252462599 · Cited by 426
Metadata
- Authors
- Gilliland, D. G., & Griffin, J. D.
- Venue
- Current Opinion in Hematology
- Published
- 2002-07
- Volume
- 9
- Issue
- 4
- Pages
- 274-281
- ISSN
- 1065-6251 (ISSN-L)
- OpenAlex
- W2007044832
- Cited by
- 202
- References
- 5
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of FLT3 in leukemia. https://app.cochat.ai/papers/10.1097/00062752-200207000-00003
- The paper
- Gilliland, D. G., & Griffin, J. D. (2002). Role of FLT3 in leukemia. Current Opinion in Hematology. https://doi.org/10.1097/00062752-200207000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.